Komal Jhaveri, MD

Articles

HR+/HER2- BC: Selecting a CDK4/6 Inhibitor in the Frontline Setting

July 4th 2022

Taking into account all 3 available CDK4/6 inhibitors in HR+/HER2- breast cancer, experts consider how they’d select frontline therapy in this setting.

CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Palbociclib

July 4th 2022

Panelists share insight on clinical trial data behind use of palbociclib in the frontline setting of HR+/HER2- breast cancer.

CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Abemaciclib and Ribociclib

June 27th 2022

Focusing on the frontline setting of HR+/HER2- breast cancer, panelists discuss clinical trial data with abemaciclib and ribociclib, respectively.

Frontline Treatment Strategies for HR+/HER2- Breast Cancer

June 27th 2022

Expert perspectives on the evolving treatment paradigm for patients receiving frontline therapy for HR+/HER2- breast cancer.

Dr. Jhaveri on Sequencing Treatments in Metastatic HER2+ Breast Cancer

December 17th 2020

Komal Jhaveri, MD, FACP, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses sequencing treatments for patients with metastatic HER2-positive breast cancer.

Dr. Jhaveri Discusses the Potential of Immunotherapy in TNBC

February 22nd 2019

Komal Jhaveri, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the potential for immunotherapy in the treatment of patients with triple-negative breast cancer (TNBC) based on results from the IMpassion130 trial.

Antibody-Drug Conjugates and T-DM1

March 21st 2014

Human epidermal growth factor receptor 2 (HER2)-positive disease accounts for 20% to 25% of breast cancers, as represented by amplification of the HER2 gene and/or HER2 protein overexpression